Biotech
Purring into the Future: Backing The Cat Health Company
Founded by two scientists, TCHC is on a mission to improve feline longevity
At Early Game Ventures, we’re excited to announce our latest move into the biotech world with a €500,000 pre-seed investment in The Cat Health Company (TCHC). Founded by two brilliant scientists, Alex Voda and Alex Bacita, TCHC is on a mission to improve feline health and longevity. With their deep expertise in the longevity field and a passion for cats, they’re tackling the high-potential niche of feline longevity research, aiming to extend the lives and health of our feline friends.
Chasing the Laser Pointer: Why TCHC Caught Our Eye
TCHC isn’t just about cute cats; it’s about leveraging cutting-edge in silico research to revolutionize drug development. In the pharmaceutical industry, in silico research is rapidly emerging as a game-changer. By using computer-driven approaches, TCHC can explore vast libraries of drug candidates faster and more cost-effectively than ever before. This approach is not only speeding up the development of new therapies but also reducing costs—a win-win for the biotech sector and, ultimately, for the cats who will benefit.
The founders of TCHC, who met during their studies at The University of Manchester, bring a powerful combination of scientific and business expertise to the table. With one of them holding an Oxford PhD in Molecular and Cellular Medicine and the other having served as a Senior Scientist at Charles River Laboratories, TCHC is well-positioned to make waves in the biotech industry. Their focus on feline health taps into a relatively underexplored market, and with the U.S. spending over $500 million annually on Halloween costumes for cats, it’s clear that people are willing to invest in their furry companions.
Nine Lives, One Big Mission: The Road Ahead for TCHC
While TCHC is laser-focused on cats for now, their ambitions go beyond just feline health. They’re starting clinical trials for their most promising therapies, with an eye on eventually expanding into longevity therapies for humans. It’s a bold vision, but with the right team and technology, they’re well on their way to making it a reality.
As Florin Visa, Partner at Early Game Ventures, said, “I’m thrilled to support TCHC. Their founders are not only brilliant Romanian scientists who deserve our full backing, but they also have a promising entrepreneurial spirit. They’ve masterfully combined their scientific expertise with a keen commercial instinct to create a venture that has the potential to revolutionize both pet care and, why not, human health.”
The Cat’s Out of the Bag: A Pawsitive Outlook for TCHC
At Early Game Ventures, we believe in backing startups that are poised to make a real difference, and The Cat Health Company is a perfect example. By focusing on feline longevity, they’re addressing a market that’s often overlooked yet full of potential. We’re proud to be part of their journey and look forward to seeing how they continue to innovate and grow.
Here’s to a future where cats live longer, healthier lives—and maybe, just maybe, humans do too.
At Early Game Ventures, we’re excited to announce our latest move into the biotech world with a €500,000 pre-seed investment in The Cat Health Company (TCHC). Founded by two brilliant scientists, Alex Voda and Alex Bacita, TCHC is on a mission to improve feline health and longevity. With their deep expertise in the longevity field and a passion for cats, they’re tackling the high-potential niche of feline longevity research, aiming to extend the lives and health of our feline friends.
Chasing the Laser Pointer: Why TCHC Caught Our Eye
TCHC isn’t just about cute cats; it’s about leveraging cutting-edge in silico research to revolutionize drug development. In the pharmaceutical industry, in silico research is rapidly emerging as a game-changer. By using computer-driven approaches, TCHC can explore vast libraries of drug candidates faster and more cost-effectively than ever before. This approach is not only speeding up the development of new therapies but also reducing costs—a win-win for the biotech sector and, ultimately, for the cats who will benefit.
The founders of TCHC, who met during their studies at The University of Manchester, bring a powerful combination of scientific and business expertise to the table. With one of them holding an Oxford PhD in Molecular and Cellular Medicine and the other having served as a Senior Scientist at Charles River Laboratories, TCHC is well-positioned to make waves in the biotech industry. Their focus on feline health taps into a relatively underexplored market, and with the U.S. spending over $500 million annually on Halloween costumes for cats, it’s clear that people are willing to invest in their furry companions.
Nine Lives, One Big Mission: The Road Ahead for TCHC
While TCHC is laser-focused on cats for now, their ambitions go beyond just feline health. They’re starting clinical trials for their most promising therapies, with an eye on eventually expanding into longevity therapies for humans. It’s a bold vision, but with the right team and technology, they’re well on their way to making it a reality.
As Florin Visa, Partner at Early Game Ventures, said, “I’m thrilled to support TCHC. Their founders are not only brilliant Romanian scientists who deserve our full backing, but they also have a promising entrepreneurial spirit. They’ve masterfully combined their scientific expertise with a keen commercial instinct to create a venture that has the potential to revolutionize both pet care and, why not, human health.”
The Cat’s Out of the Bag: A Pawsitive Outlook for TCHC
At Early Game Ventures, we believe in backing startups that are poised to make a real difference, and The Cat Health Company is a perfect example. By focusing on feline longevity, they’re addressing a market that’s often overlooked yet full of potential. We’re proud to be part of their journey and look forward to seeing how they continue to innovate and grow.
Here’s to a future where cats live longer, healthier lives—and maybe, just maybe, humans do too.
At Early Game Ventures, we’re excited to announce our latest move into the biotech world with a €500,000 pre-seed investment in The Cat Health Company (TCHC). Founded by two brilliant scientists, Alex Voda and Alex Bacita, TCHC is on a mission to improve feline health and longevity. With their deep expertise in the longevity field and a passion for cats, they’re tackling the high-potential niche of feline longevity research, aiming to extend the lives and health of our feline friends.
Chasing the Laser Pointer: Why TCHC Caught Our Eye
TCHC isn’t just about cute cats; it’s about leveraging cutting-edge in silico research to revolutionize drug development. In the pharmaceutical industry, in silico research is rapidly emerging as a game-changer. By using computer-driven approaches, TCHC can explore vast libraries of drug candidates faster and more cost-effectively than ever before. This approach is not only speeding up the development of new therapies but also reducing costs—a win-win for the biotech sector and, ultimately, for the cats who will benefit.
The founders of TCHC, who met during their studies at The University of Manchester, bring a powerful combination of scientific and business expertise to the table. With one of them holding an Oxford PhD in Molecular and Cellular Medicine and the other having served as a Senior Scientist at Charles River Laboratories, TCHC is well-positioned to make waves in the biotech industry. Their focus on feline health taps into a relatively underexplored market, and with the U.S. spending over $500 million annually on Halloween costumes for cats, it’s clear that people are willing to invest in their furry companions.
Nine Lives, One Big Mission: The Road Ahead for TCHC
While TCHC is laser-focused on cats for now, their ambitions go beyond just feline health. They’re starting clinical trials for their most promising therapies, with an eye on eventually expanding into longevity therapies for humans. It’s a bold vision, but with the right team and technology, they’re well on their way to making it a reality.
As Florin Visa, Partner at Early Game Ventures, said, “I’m thrilled to support TCHC. Their founders are not only brilliant Romanian scientists who deserve our full backing, but they also have a promising entrepreneurial spirit. They’ve masterfully combined their scientific expertise with a keen commercial instinct to create a venture that has the potential to revolutionize both pet care and, why not, human health.”
The Cat’s Out of the Bag: A Pawsitive Outlook for TCHC
At Early Game Ventures, we believe in backing startups that are poised to make a real difference, and The Cat Health Company is a perfect example. By focusing on feline longevity, they’re addressing a market that’s often overlooked yet full of potential. We’re proud to be part of their journey and look forward to seeing how they continue to innovate and grow.
Here’s to a future where cats live longer, healthier lives—and maybe, just maybe, humans do too.
At Early Game Ventures, we’re excited to announce our latest move into the biotech world with a €500,000 pre-seed investment in The Cat Health Company (TCHC). Founded by two brilliant scientists, Alex Voda and Alex Bacita, TCHC is on a mission to improve feline health and longevity. With their deep expertise in the longevity field and a passion for cats, they’re tackling the high-potential niche of feline longevity research, aiming to extend the lives and health of our feline friends.
Chasing the Laser Pointer: Why TCHC Caught Our Eye
TCHC isn’t just about cute cats; it’s about leveraging cutting-edge in silico research to revolutionize drug development. In the pharmaceutical industry, in silico research is rapidly emerging as a game-changer. By using computer-driven approaches, TCHC can explore vast libraries of drug candidates faster and more cost-effectively than ever before. This approach is not only speeding up the development of new therapies but also reducing costs—a win-win for the biotech sector and, ultimately, for the cats who will benefit.
The founders of TCHC, who met during their studies at The University of Manchester, bring a powerful combination of scientific and business expertise to the table. With one of them holding an Oxford PhD in Molecular and Cellular Medicine and the other having served as a Senior Scientist at Charles River Laboratories, TCHC is well-positioned to make waves in the biotech industry. Their focus on feline health taps into a relatively underexplored market, and with the U.S. spending over $500 million annually on Halloween costumes for cats, it’s clear that people are willing to invest in their furry companions.
Nine Lives, One Big Mission: The Road Ahead for TCHC
While TCHC is laser-focused on cats for now, their ambitions go beyond just feline health. They’re starting clinical trials for their most promising therapies, with an eye on eventually expanding into longevity therapies for humans. It’s a bold vision, but with the right team and technology, they’re well on their way to making it a reality.
As Florin Visa, Partner at Early Game Ventures, said, “I’m thrilled to support TCHC. Their founders are not only brilliant Romanian scientists who deserve our full backing, but they also have a promising entrepreneurial spirit. They’ve masterfully combined their scientific expertise with a keen commercial instinct to create a venture that has the potential to revolutionize both pet care and, why not, human health.”
The Cat’s Out of the Bag: A Pawsitive Outlook for TCHC
At Early Game Ventures, we believe in backing startups that are poised to make a real difference, and The Cat Health Company is a perfect example. By focusing on feline longevity, they’re addressing a market that’s often overlooked yet full of potential. We’re proud to be part of their journey and look forward to seeing how they continue to innovate and grow.
Here’s to a future where cats live longer, healthier lives—and maybe, just maybe, humans do too.
Other Stories
Other Stories
Other Stories
Early Game Ventures Fund II is a venture capital fund capitalized by the Recovery Equity Fund, managed by the European Investment Fund, and financed by thePNRR within the Next Generation EU.
Early Game Ventures Fund I is a venture capital fund funded mostly through the Competitiveness Operational Program 2014-2020, co-funded by the European Regional Development Fund.
Early Game Ventures Fund II is a venture capital fund capitalized by the Recovery Equity Fund, managed by the European Investment Fund, and financed by thePNRR within the Next Generation EU.
Early Game Ventures Fund I is a venture capital fund funded mostly through the Competitiveness Operational Program 2014-2020, co-funded by the European Regional Development Fund.
Early Game Ventures Fund II is a venture capital fund capitalized by the Recovery Equity Fund, managed by the European Investment Fund, and financed by thePNRR within the Next Generation EU.
Early Game Ventures Fund I is a venture capital fund funded mostly through the Competitiveness Operational Program 2014-2020, co-funded by the European Regional Development Fund.